Does the media favor FULC or XLO?

In the previous week, Xilio Therapeutics had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for Xilio Therapeutics and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat Xilio Therapeutics' score of 0.38 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is XLO or IVVD more profitable?

Xilio Therapeutics has a net margin of -58.52% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Xilio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Xilio Therapeutics -58.52% -151.42% -27.61% Invivyd -138.90% -53.48% -41.56%

Does the media refer more to XLO or IVVD?

In the previous week, Invivyd had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Invivyd and 3 mentions for Xilio Therapeutics. Invivyd's average media sentiment score of 0.46 beat Xilio Therapeutics' score of 0.38 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CHRS or XLO?

In the previous week, Xilio Therapeutics had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for Xilio Therapeutics and 2 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 1.28 beat Xilio Therapeutics' score of 0.38 indicating that Coherus Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is XLO or NKTX more profitable?

Nkarta has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Nkarta's return on equity of -30.90% beat Xilio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Xilio Therapeutics -58.52% -151.42% -27.61% Nkarta N/A -30.90% -24.20%

Xilio Therapeutics (XLO) Competitors

$9.24 +0.14 (+1.54%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$9.25 +0.01 (+0.11%)

As of 07/13/2026 04:04 PM Eastern

Compare

XLO vs. FULC, AVXL, IVVD, CHRS, and NKTX

Should you buy Xilio Therapeutics stock or one of its competitors? MarketBeat compares Xilio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xilio Therapeutics include Fulcrum Therapeutics (FULC), Anavex Life Sciences (AVXL), Invivyd (IVVD), Coherus Oncology (CHRS), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry.

How does Xilio Therapeutics compare to Fulcrum Therapeutics?

Fulcrum Therapeutics (NASDAQ:FULC) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Xilio Therapeutics had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for Xilio Therapeutics and 2 mentions for Fulcrum Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.45 beat Xilio Therapeutics' score of 0.38 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xilio Therapeutics has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	2.95	-$74.88M	-$1.15	N/A
Xilio Therapeutics	$43.77M	1.39	-$35.04M	-$3.55	N/A

Fulcrum Therapeutics presently has a consensus price target of $8.20, indicating a potential upside of 131.64%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 203.03%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Fulcrum Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Fulcrum Therapeutics' return on equity of -27.80% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Fulcrum Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

Summary

Fulcrum Therapeutics beats Xilio Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Xilio Therapeutics compare to Anavex Life Sciences?

Xilio Therapeutics (NASDAQ:XLO) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Anavex Life Sciences has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Anavex Life Sciences' return on equity of -38.76% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Anavex Life Sciences	N/A	-38.76%	-35.01%

In the previous week, Xilio Therapeutics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Xilio Therapeutics and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Xilio Therapeutics' score of 0.38 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Xilio Therapeutics	Neutral
Anavex Life Sciences	Very Positive

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Xilio Therapeutics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.39	-$35.04M	-$3.55	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Xilio Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Xilio Therapeutics currently has a consensus price target of $28.00, indicating a potential upside of 203.03%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 807.80%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Xilio Therapeutics and Anavex Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Xilio Therapeutics compare to Invivyd?

Xilio Therapeutics (NASDAQ:XLO) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Xilio Therapeutics presently has a consensus target price of $28.00, suggesting a potential upside of 203.03%. Invivyd has a consensus target price of $8.00, suggesting a potential upside of 915.87%. Given Invivyd's higher probable upside, analysts clearly believe Invivyd is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Xilio Therapeutics has higher earnings, but lower revenue than Invivyd. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.39	-$35.04M	-$3.55	N/A
Invivyd	$53.43M	4.34	-$52.49M	-$0.31	N/A

Xilio Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Xilio Therapeutics has a net margin of -58.52% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Invivyd	-138.90%	-53.48%	-41.56%

In the previous week, Invivyd had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Invivyd and 3 mentions for Xilio Therapeutics. Invivyd's average media sentiment score of 0.46 beat Xilio Therapeutics' score of 0.38 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Invivyd beats Xilio Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Xilio Therapeutics compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Coherus Oncology has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

Coherus Oncology presently has a consensus price target of $8.67, indicating a potential upside of 489.57%. Xilio Therapeutics has a consensus price target of $28.00, indicating a potential upside of 203.03%. Given Coherus Oncology's stronger consensus rating and higher probable upside, equities research analysts plainly believe Coherus Oncology is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Xilio Therapeutics had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for Xilio Therapeutics and 2 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 1.28 beat Xilio Therapeutics' score of 0.38 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coherus Oncology has higher earnings, but lower revenue than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.38	$168.02M	$1.67	0.88
Xilio Therapeutics	$43.77M	1.39	-$35.04M	-$3.55	N/A

Coherus Oncology has a net margin of 397.30% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Summary

Coherus Oncology beats Xilio Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Xilio Therapeutics compare to Nkarta?

Xilio Therapeutics (NASDAQ:XLO) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Xilio Therapeutics had 2 more articles in the media than Nkarta. MarketBeat recorded 3 mentions for Xilio Therapeutics and 1 mentions for Nkarta. Nkarta's average media sentiment score of 1.87 beat Xilio Therapeutics' score of 0.38 indicating that Nkarta is being referred to more favorably in the news media.

Company	Overall Sentiment
Xilio Therapeutics	Neutral
Nkarta	Very Positive

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by insiders. Comparatively, 9.8% of Nkarta shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nkarta has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Nkarta's return on equity of -30.90% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Nkarta	N/A	-30.90%	-24.20%

Xilio Therapeutics has higher revenue and earnings than Nkarta. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.39	-$35.04M	-$3.55	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

Xilio Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 203.03%. Nkarta has a consensus target price of $10.75, indicating a potential upside of 285.30%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Xilio Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Summary

Nkarta beats Xilio Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XLO vs. The Competition

Export

Metric	Xilio Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$59.83M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-2.60	20.85	27.11	24.26
Price / Sales	1.39	314.01	589.96	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.26	8.49	10.74	6.29
Net Income	-$35.04M	$23.83M	$3.58B	$330.66M
7 Day Performance	-0.75%	-3.56%	-2.11%	-1.35%
1 Month Performance	11.19%	6.31%	3.27%	-0.64%
1 Year Performance	-10.76%	48.30%	26.31%	19.08%

Xilio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XLO Xilio Therapeutics	2.092 of 5 stars	$9.24 +1.5%	$28.00 +203.0%	-10.1%	$59.83M	$43.77M	N/A	70
FULC Fulcrum Therapeutics	3.5877 of 5 stars	$3.77 +1.3%	$8.20 +117.5%	-54.8%	$247.88M	$80M	N/A	100	News Coverage
AVXL Anavex Life Sciences	2.8313 of 5 stars	$2.71 +1.9%	$21.33 +687.2%	-78.8%	$246.51M	N/A	N/A	40	Positive News Upcoming Earnings
IVVD Invivyd	3.5569 of 5 stars	$0.94 +12.9%	$8.00 +749.4%	+6.6%	$245.70M	$53.43M	N/A	100	Gap Up
CHRS Coherus Oncology	2.8055 of 5 stars	$1.67 +7.1%	$8.67 +419.0%	+67.0%	$240.63M	$42.17M	1.00	330	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XLO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xilio Therapeutics (XLO) Competitors

XLO vs. FULC, AVXL, IVVD, CHRS, and NKTX

How does Xilio Therapeutics compare to Fulcrum Therapeutics?

Summary

How does Xilio Therapeutics compare to Anavex Life Sciences?

Summary

How does Xilio Therapeutics compare to Invivyd?

Summary

How does Xilio Therapeutics compare to Coherus Oncology?

Summary

How does Xilio Therapeutics compare to Nkarta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xilio Therapeutics (XLO) Competitors

XLO vs. FULC, AVXL, IVVD, CHRS, and NKTX

How does Xilio Therapeutics compare to Fulcrum Therapeutics?

Do insiders and institutionals have more ownership in FULC or XLO?

Does the media favor FULC or XLO?

Which has higher valuation and earnings, FULC or XLO?

Do analysts rate FULC or XLO?

Is FULC or XLO more profitable?

Which has more risk & volatility, FULC or XLO?

Summary

How does Xilio Therapeutics compare to Anavex Life Sciences?

Is XLO or AVXL more profitable?

Does the media refer more to XLO or AVXL?

Do institutionals and insiders have more ownership in XLO or AVXL?

Which has better earnings & valuation, XLO or AVXL?

Which has more volatility & risk, XLO or AVXL?

Do analysts prefer XLO or AVXL?

Summary

How does Xilio Therapeutics compare to Invivyd?

Do analysts rate XLO or IVVD?

Which has better valuation and earnings, XLO or IVVD?

Which has more risk & volatility, XLO or IVVD?

Is XLO or IVVD more profitable?

Does the media refer more to XLO or IVVD?

Do institutionals and insiders hold more shares of XLO or IVVD?

Summary

How does Xilio Therapeutics compare to Coherus Oncology?

Do institutionals and insiders have more ownership in CHRS or XLO?

Which has more risk and volatility, CHRS or XLO?

Do analysts prefer CHRS or XLO?

Does the media favor CHRS or XLO?

Which has stronger valuation & earnings, CHRS or XLO?

Is CHRS or XLO more profitable?

Summary

How does Xilio Therapeutics compare to Nkarta?

Does the media refer more to XLO or NKTX?

Do insiders and institutionals have more ownership in XLO or NKTX?

Is XLO or NKTX more profitable?

Which has stronger valuation & earnings, XLO or NKTX?

Do analysts rate XLO or NKTX?

Which has more volatility & risk, XLO or NKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools